Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.

Se Min Hwang, Hack Lyoung Kim, Kyueng Whan Min, Min Kim, Jae Sung Lim, Jin Man Choi, Byung-Chul Chun, Min Jeong Kim, Sang Min Lee, Seung Young Kim, Han Ho Jeon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The first large-scale outbreaks of respiratory disease in the 21st century were caused by the influenza A (H1N1) virus in 2009, which affected mostly young adults. The M59 vaccine was developed to control pandemic influenza A (H1N1). However, the complications arising from the use of the non-adjuvanted and adjuvanted vaccines in young male Korean soldiers have not previously been evaluated and compared. We conducted a prospective multicenter study of 2,864 healthy male soldiers aged 19 to 25 years to evaluate the adverse events associated with both the MF59-adjuvanted and non-adjuvanted forms of the influenza A/California/2009 (H1N1) surface-antigen vaccine. In most cases, the adverse-event symptoms were mild, and the most frequent adverse events were swelling at the injection site and myalgia, which were noted in 4.8% and 10.7% of participants, respectively. Administration of the MF59-adjuvanted vaccine was associated with an increased incidence of local (crude odds ratio [cOR], 1.56; 95% confidence interval [CI], 1.11-2.29) and systemic adverse events (cOR, 1.64; 95% CI, 1.29-2.07) after vaccination. Atopic dermatitis (adjusted OR [aOR], 2.32; 95% CI, 0.99-5.46) might be the choice risk factor for local adverse events, and adjuvant use (aOR, 1.35; 95% CI, 1.03-1.78) was a significant predictor of systemic adverse events in healthy young male Korean soldiers.

Original languageEnglish
Pages (from-to)193-197
Number of pages5
JournalJapanese Journal of Infectious Diseases
Volume65
Issue number3
Publication statusPublished - 2012 Sep 26
Externally publishedYes

Fingerprint

Military Personnel
Vaccines
Confidence Intervals
Human Influenza
Odds Ratio
H1N1 Subtype Influenza A Virus
Myalgia
Influenza A virus
Pandemics
Atopic Dermatitis
Surface Antigens
Multicenter Studies
Disease Outbreaks
Young Adult
Vaccination
Prospective Studies
Injections
MF59 oil emulsion
Incidence

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. / Hwang, Se Min; Kim, Hack Lyoung; Min, Kyueng Whan; Kim, Min; Lim, Jae Sung; Choi, Jin Man; Chun, Byung-Chul; Kim, Min Jeong; Lee, Sang Min; Kim, Seung Young; Jeon, Han Ho.

In: Japanese Journal of Infectious Diseases, Vol. 65, No. 3, 26.09.2012, p. 193-197.

Research output: Contribution to journalArticle

Hwang, SM, Kim, HL, Min, KW, Kim, M, Lim, JS, Choi, JM, Chun, B-C, Kim, MJ, Lee, SM, Kim, SY & Jeon, HH 2012, 'Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.', Japanese Journal of Infectious Diseases, vol. 65, no. 3, pp. 193-197.
Hwang, Se Min ; Kim, Hack Lyoung ; Min, Kyueng Whan ; Kim, Min ; Lim, Jae Sung ; Choi, Jin Man ; Chun, Byung-Chul ; Kim, Min Jeong ; Lee, Sang Min ; Kim, Seung Young ; Jeon, Han Ho. / Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. In: Japanese Journal of Infectious Diseases. 2012 ; Vol. 65, No. 3. pp. 193-197.
@article{fdd29948f0d940ef9898afa64f46bd1f,
title = "Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.",
abstract = "The first large-scale outbreaks of respiratory disease in the 21st century were caused by the influenza A (H1N1) virus in 2009, which affected mostly young adults. The M59 vaccine was developed to control pandemic influenza A (H1N1). However, the complications arising from the use of the non-adjuvanted and adjuvanted vaccines in young male Korean soldiers have not previously been evaluated and compared. We conducted a prospective multicenter study of 2,864 healthy male soldiers aged 19 to 25 years to evaluate the adverse events associated with both the MF59-adjuvanted and non-adjuvanted forms of the influenza A/California/2009 (H1N1) surface-antigen vaccine. In most cases, the adverse-event symptoms were mild, and the most frequent adverse events were swelling at the injection site and myalgia, which were noted in 4.8{\%} and 10.7{\%} of participants, respectively. Administration of the MF59-adjuvanted vaccine was associated with an increased incidence of local (crude odds ratio [cOR], 1.56; 95{\%} confidence interval [CI], 1.11-2.29) and systemic adverse events (cOR, 1.64; 95{\%} CI, 1.29-2.07) after vaccination. Atopic dermatitis (adjusted OR [aOR], 2.32; 95{\%} CI, 0.99-5.46) might be the choice risk factor for local adverse events, and adjuvant use (aOR, 1.35; 95{\%} CI, 1.03-1.78) was a significant predictor of systemic adverse events in healthy young male Korean soldiers.",
author = "Hwang, {Se Min} and Kim, {Hack Lyoung} and Min, {Kyueng Whan} and Min Kim and Lim, {Jae Sung} and Choi, {Jin Man} and Byung-Chul Chun and Kim, {Min Jeong} and Lee, {Sang Min} and Kim, {Seung Young} and Jeon, {Han Ho}",
year = "2012",
month = "9",
day = "26",
language = "English",
volume = "65",
pages = "193--197",
journal = "Japanese Journal of Infectious Diseases",
issn = "1344-6304",
publisher = "National Institute of Health",
number = "3",

}

TY - JOUR

T1 - Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.

AU - Hwang, Se Min

AU - Kim, Hack Lyoung

AU - Min, Kyueng Whan

AU - Kim, Min

AU - Lim, Jae Sung

AU - Choi, Jin Man

AU - Chun, Byung-Chul

AU - Kim, Min Jeong

AU - Lee, Sang Min

AU - Kim, Seung Young

AU - Jeon, Han Ho

PY - 2012/9/26

Y1 - 2012/9/26

N2 - The first large-scale outbreaks of respiratory disease in the 21st century were caused by the influenza A (H1N1) virus in 2009, which affected mostly young adults. The M59 vaccine was developed to control pandemic influenza A (H1N1). However, the complications arising from the use of the non-adjuvanted and adjuvanted vaccines in young male Korean soldiers have not previously been evaluated and compared. We conducted a prospective multicenter study of 2,864 healthy male soldiers aged 19 to 25 years to evaluate the adverse events associated with both the MF59-adjuvanted and non-adjuvanted forms of the influenza A/California/2009 (H1N1) surface-antigen vaccine. In most cases, the adverse-event symptoms were mild, and the most frequent adverse events were swelling at the injection site and myalgia, which were noted in 4.8% and 10.7% of participants, respectively. Administration of the MF59-adjuvanted vaccine was associated with an increased incidence of local (crude odds ratio [cOR], 1.56; 95% confidence interval [CI], 1.11-2.29) and systemic adverse events (cOR, 1.64; 95% CI, 1.29-2.07) after vaccination. Atopic dermatitis (adjusted OR [aOR], 2.32; 95% CI, 0.99-5.46) might be the choice risk factor for local adverse events, and adjuvant use (aOR, 1.35; 95% CI, 1.03-1.78) was a significant predictor of systemic adverse events in healthy young male Korean soldiers.

AB - The first large-scale outbreaks of respiratory disease in the 21st century were caused by the influenza A (H1N1) virus in 2009, which affected mostly young adults. The M59 vaccine was developed to control pandemic influenza A (H1N1). However, the complications arising from the use of the non-adjuvanted and adjuvanted vaccines in young male Korean soldiers have not previously been evaluated and compared. We conducted a prospective multicenter study of 2,864 healthy male soldiers aged 19 to 25 years to evaluate the adverse events associated with both the MF59-adjuvanted and non-adjuvanted forms of the influenza A/California/2009 (H1N1) surface-antigen vaccine. In most cases, the adverse-event symptoms were mild, and the most frequent adverse events were swelling at the injection site and myalgia, which were noted in 4.8% and 10.7% of participants, respectively. Administration of the MF59-adjuvanted vaccine was associated with an increased incidence of local (crude odds ratio [cOR], 1.56; 95% confidence interval [CI], 1.11-2.29) and systemic adverse events (cOR, 1.64; 95% CI, 1.29-2.07) after vaccination. Atopic dermatitis (adjusted OR [aOR], 2.32; 95% CI, 0.99-5.46) might be the choice risk factor for local adverse events, and adjuvant use (aOR, 1.35; 95% CI, 1.03-1.78) was a significant predictor of systemic adverse events in healthy young male Korean soldiers.

UR - http://www.scopus.com/inward/record.url?scp=84866500944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866500944&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 193

EP - 197

JO - Japanese Journal of Infectious Diseases

JF - Japanese Journal of Infectious Diseases

SN - 1344-6304

IS - 3

ER -